{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:21:25Z","timestamp":1768029685193,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CONACYT","award":["S0008-FONSEC SSA\/IMSS\/ISSSTE-26172"],"award-info":[{"award-number":["S0008-FONSEC SSA\/IMSS\/ISSSTE-26172"]}]},{"name":"CONACYT","award":["fellowship number 241787"],"award-info":[{"award-number":["fellowship number 241787"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of present study is to measure plasma clozapine (CLZ) and N-desmethyl clozapine (DMC) as biomarkers to correlate drug concentrations with the appearance of preclinical adverse hematic effects.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A high-performance liquid chromatographic method, using a diode-array (ultraviolet) detector, was validated to obtain reliable concentrations of CLZ and DMC, its main metabolite, in plasma of 41 schizophrenic patients taking CLZ. Blood neutrophils and leucocytes counting were concurrently assessed as a proxy to subclinical adverse reactions.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analytical method employed was linear, reproducible, and stable to measure concentrations of CLZ between 30 and 1000\u2009ng\/mL, while 12.5\u2013560\u2009ng\/mL of the metabolite. The method allowed us to correlate CLZ plasma concentrations, the time taking CLZ and CLZ dose as determinants of neutrophils\u2019 counting with a R<jats:sup>2<\/jats:sup>\u2009=\u20090.447, using a multiple regression analysis model. Likewise, the correlation of leucocyte counting vs CLZ plasma levels and CLZ time, showed a R<jats:sup>2<\/jats:sup>\u2009=\u20090.461. DMC correlated significantly with both neutrophils and leucocytes counting, but was excluded from the regression when CLZ concentration was included in the model. Finally, no other hematological adverse reactions were recorded. One patient presented a cardiovascular complication. The negative correlation between clozapine and neutrophil count observed in patients, suggest that CLZ itself, but not DMC, could be related to hematologic side-effects.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings of this study, demonstrate for the first time, that plasma levels of CLZ and time taking the drug are independent determinants of blood neutrophils and leucocytes, so the monitoring of plasma CLZ may be useful in the clinic practice to determine safe dosing of the drug.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-019-2286-1","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T12:03:54Z","timestamp":1570622634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clozapine and desmethylclozapine: correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia"],"prefix":"10.1186","volume":"19","author":[{"given":"Mayela","family":"Vaquero-Baez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"D\u00edaz-Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Trist\u00e1n-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Avi\u00f1a-Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Torner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Ram\u00edrez-Berm\u00fadez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"2286_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12888-015-0578-7","volume":"15","author":"JC Simeone","year":"2015","unstructured":"Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990-2013: a systematic literature review. BMC Psychiatry. 2015;15:193\u2013207.","journal-title":"BMC Psychiatry"},{"key":"2286_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","volume":"29","author":"JL Kennedy","year":"2014","unstructured":"Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63\u201376.","journal-title":"Int Clin Psychopharmacol"},{"key":"2286_CR3","doi-asserted-by":"publisher","first-page":"S1135","DOI":"10.1016\/S0924-977X(17)31966-1","volume":"27","author":"O Howes","year":"2017","unstructured":"Howes O. When the drugs don\u2019t work: the neurobiology of TRS and implications for new therapies. Eur Neuropsychopharmacol. 2017;27:S1135\u20136.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2286_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0957154X07070335","volume":"18","author":"J Crilly","year":"2007","unstructured":"Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18:39\u201360.","journal-title":"Hist Psychiatry"},{"key":"2286_CR5","first-page":"CD000059","volume":"21","author":"A Essali","year":"2009","unstructured":"Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;21:CD000059.","journal-title":"Cochrane Database Syst Rev"},{"key":"2286_CR6","unstructured":"IBM Micromedex DRUGDEX (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at \n                    https:\/\/www.micromedexsolutions.com\n                    \n                  . )."},{"issue":"3","key":"2286_CR7","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with Clozaril National Registry. J Clin Psychiatry. 1998;59(3):3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"2286_CR8","doi-asserted-by":"crossref","unstructured":"Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E. Correlation between serum concentrations of N-Desmethylclozapine and granulocyte levels in patients with schizophrenia: a retrospective observational study. CNS Drugs. 2017;57\u201364.","DOI":"10.1007\/s40263-017-0469-1"},{"key":"2286_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov D, Dean O, Lu D, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Ording-Jespersen S, Litlle J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia \u2013 a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361\u20138.","journal-title":"Biol Psychiatry"},{"key":"2286_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-244X-13-153","volume":"13","author":"S Gibson","year":"2013","unstructured":"Gibson S, Brand SL, Burt S, Boden ZVR, Benson O. Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. BMC Psychiatry. 2013;13:153.","journal-title":"BMC Psychiatry"},{"key":"2286_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","volume":"36","author":"CJ Bachmann","year":"2017","unstructured":"Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Fust\u00e9 AC, Furu K, Garuolien\u00e9 D, Hoffmann F, Hollingworth S, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, L\u00f3pez SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Piovani D, Reutfors J, Saastomoinen LK, Sato I, Shuiling-Veninga CCM, Shyu YC, Siskind D, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Zo\u00ebga H, Taylor D. Internacional trends in clozpine use: a study in 17 countries. Acta Psychiatr Scand. 2017;36:37\u201351.","journal-title":"Acta Psychiatr Scand"},{"key":"2286_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-244X-14-102","volume":"14","author":"S Warnez","year":"2014","unstructured":"Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102\u20136.","journal-title":"BMC Psychiatry"},{"issue":"Suppl 8","key":"2286_CR13","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/clinchem\/39.8.1656","volume":"39","author":"SA Volpicelli","year":"1993","unstructured":"Volpicelli SA, Centorrino F, Puopolo PR, Kando J, Frankenburg FR, Baldessarini RJ, Flood JG. Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. Clin Chem. 1993;39(Suppl 8):1656\u20139.","journal-title":"Clin Chem"},{"key":"2286_CR14","unstructured":"Guidence for Industry, Bioanalytical method validation, US Department of Health and Human Services, Food and Drug Administration, CDER, CVM, (May 2001)."},{"key":"2286_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","volume":"161","author":"TP Glimer","year":"2004","unstructured":"Glimer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garc\u00eda P, Jeste DV. Adherence to treatment with antipsychotic medication and health care cost among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692\u20139.","journal-title":"Am J Psychiatry"},{"key":"2286_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1176\/ajp.152.3.453","volume":"152","author":"J de Leon","year":"1995","unstructured":"de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiologic survey in a state hospital. Am J Psychiatry. 1995;152:453\u20135.","journal-title":"Am J Psychiatry"},{"key":"2286_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0924-977X(99)00033-4","volume":"9","author":"B Buur-Rasmussen","year":"1999","unstructured":"Buur-Rasmussen B, Br\u00f8sen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol. 1999;9:453\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2286_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s002130050028","volume":"148","author":"A Spina","year":"2000","unstructured":"Spina A, Avenoso G, Facciol\u00e0 MG, Scordo MG, Ancione M, Madia AG, Ventimiglia A, Perucca E. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology. 2000;148:83\u20139.","journal-title":"Psychopharmacology."},{"key":"2286_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","volume":"25","author":"M Wici\u0144ski","year":"2018","unstructured":"Wici\u0144ski M, Weclewicz MM. Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol. 2018;25:22\u20138.","journal-title":"Curr Opin Hematol"},{"key":"2286_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1021\/tx500183x","volume":"27","author":"N Winnie","year":"2014","unstructured":"Winnie N, Rossoune K, Uetrecht J. Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis. Chem Res Toxicol. 2014;27:1104\u20138.","journal-title":"Chem Res Toxicol"},{"key":"2286_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.pnpbp.2007.03.009","volume":"31","author":"N Bergemann","year":"2007","unstructured":"Bergemann N, Abu-Tair F, Aderjan R, Kopitz J. High clozapine concentrations in leukocytes in a patient who developed leukocytopenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:1068\u201371.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2286_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40263-017-0469-1","volume":"31","author":"RL Smith","year":"2017","unstructured":"Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E. Correlation between serum concentrations of N-Desmethylclozapine and granulocyte levels in patients with schizophrenia: a retrospective observational study. CNS Drugs. 2017;31:991\u20137.","journal-title":"CNS Drugs"},{"issue":"3","key":"2286_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/070674370204700306","volume":"47","author":"L Oyewumi","year":"2002","unstructured":"Oyewumi L, Cernovsky Z, Freeman D, Streiner D. Relation of blood counts during clozapine treatment to serum concentrations of clozapine and nor-clozapine. Can J Psychiatr. 2002;47(3):257\u201361.","journal-title":"Can J Psychiatr"},{"key":"2286_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/npp.1994.34","volume":"11","author":"M Hasegawa","year":"1994","unstructured":"Hasegawa M, Cola P, Meltzer H. Plasma clozapine and desmethyl clozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology. 1994;11:45\u20137.","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"2286_CR25","first-page":"1463","volume":"275","author":"J Maggs","year":"1995","unstructured":"Maggs J, Williams D, Pirmohamed M. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther. 1995;275(3):1463\u201375.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2286-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-019-2286-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-019-2286-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T23:06:48Z","timestamp":1602112008000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-019-2286-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1186\/s12888-019-2286-1","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the National Institute of Neurology and Neurosurgery Bioethics Committee. Written informed consent to participate was obtained from all subjects before enrollment in the study, from a relative or guardian for each patient and two witnesses, according to Mexican Code of Health Regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest and no competing interests associated with the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}